Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine

Edoardo Caronna; Amaal J. Starling

doi:10.1016/j.ncl.2020.09.001

Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine

Edoardo Caronna, Amaal J. Starling

Neurology

Research output: Contribution to journal › Review article › peer-review

Abstract

The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders.

Original language	English (US)
Pages (from-to)	1-19
Number of pages	19
Journal	Neurologic clinics
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/j.ncl.2020.09.001
State	Published - Feb 2021

Keywords

CGRP
Efficacy
Gepants
Migraine
Monoclonal antibodies
Safety
Treatment

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/j.ncl.2020.09.001

Cite this

@article{70e448134b6e4511adbd3fbfbe222dfb,

title = "Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine",

abstract = "The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, na{\"i}ve and refractory patients and even between migraine and other headache disorders.",

keywords = "CGRP, Efficacy, Gepants, Migraine, Monoclonal antibodies, Safety, Treatment",

author = "Edoardo Caronna and Starling, {Amaal J.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = feb,

doi = "10.1016/j.ncl.2020.09.001",

language = "English (US)",

volume = "39",

pages = "1--19",

journal = "Neurologic clinics",

issn = "0733-8619",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine

AU - Caronna, Edoardo

AU - Starling, Amaal J.

PY - 2021/2

Y1 - 2021/2

N2 - The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders.

AB - The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders.

KW - CGRP

KW - Efficacy

KW - Gepants

KW - Migraine

KW - Monoclonal antibodies

KW - Safety

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85095839944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095839944&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2020.09.001

DO - 10.1016/j.ncl.2020.09.001

M3 - Review article

C2 - 33223077

AN - SCOPUS:85095839944

SN - 0733-8619

VL - 39

SP - 1

EP - 19

JO - Neurologic clinics

JF - Neurologic clinics

IS - 1

ER -

Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this